Table 3 Change from baseline at week 52 in the subpopulations of participants taking MAO-B inhibitors at baseline and those who were treatment-naive at baseline

	Placebo			Prasinezumab pooled
	MAO-B (n = 38)	Treatment-naive (n = 67)	All (n = 105)	MAO-B (n = 77)			Treatment-naive (n = 134)
	Adjusted mean (s.e.)	Adjusted mean (s.e.)	Adjusted mean (s.e.)	Difference in adjusted means (s.e.)	80% CI	% RR	Difference in adjusted means (s.e.)	80% CI	% RR
MDS-UPDRS Part III
Hypothetical strategy^a	6.82 (1.371) n = 28	5.04 (1.163) n = 48	5.57 (0.897) n = 76	−2.66 (1.713) n = 55	−4.87, −0.45	−39.0	−0.87 (1.411) n = 92	−2.69, 0.94	−17.3
Treatment policy OFF^b	4.79 (1.214) n = 36	3.10 (1.048) n = 65	3.56 (0.800) n = 101	−2.60 (1.476) n = 76	−4.51, −0.70	−54.3	0.53 (1.267) n = 125	−1.10, 2.16	+17.1
Treatment policy ON^b	4.18 (1.248) n = 38	2.01 (1.109) n = 67	2.66 (0.840) n = 105	−2.60 (1.532) n = 76	−4.57, −0.63	−62.2	0.32 (1.340) n = 130	−1.40, 2.04	+15.9
MDS-UPDRS Part II
Hypothetical strategy^a	2.40 (0.635) n = 28	2.89 (0.467) n = 48	2.75 (0.373) n = 76	0.20 (0.773) n = 55	−0.80, 1.20	+8.3	0.10 (0.567) n = 92	−0.63, 0.83	+3.5
Treatment policy^b	1.21 (0.592) n = 38	1.63 (0.438) n = 67	1.47 (0.353) n = 105	0.22 (0.721) n = 76	−0.71, 1.15	+18.2	0.25 (0.531) n = 129	−0.43, 0.93	+15.3
MDS-UPDRS Part I
Hypothetical strategy^a	1.28 (0.466) n = 28	0.38 (0.371) n = 48	0.77 (0.295) n = 76	−0.44 (0.567) n = 55	−1.17, 0.29	−34.4	0.30 (0.447) n = 92	−0.27, 0.88	+78.9
Treatment policy^b	0.50 (0.452) n = 37	0.10 (0.375) n = 67	0.20 (0.292) n = 104	0.03 (0.549) n = 76	−0.68, 0.73	+6.0	0.65 (0.453) n = 125	0.06, 1.23	+650.0

^a‘Hypothetical strategy’ assumes a scenario in which the events of start of symptomatic therapy or change in MAO-B inhibitor dose did not occur (performed for the mITT population).
^b‘Treatment policy strategy’ in which the treatment effect is estimated irrespective of symptomatic treatment start or changes in MAO-B inhibitor treatment (performed for the intention-to-treat population). CI, confidence interval; MAO-B, monoamine oxidase-B; MDS-UPDRS, Movement Disorder Society-Unified Parkinson’s Disease Rating Scale; mITT, modified intention-to-treat; %RR, percent relative reduction; s.e., standard error.

Search